Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Hyperplasia Stories

2009-04-24 06:30:00

SEATTLE, April 24 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced the following data presentations taking place at the American Urological Association's (AUA) Annual Meeting in Chicago, as well as a Dendreon-sponsored IMPACT data webcast conference call: April 28, 2009, 2:20 p.m. CDT - "A randomized, double-blind, placebo-controlled, multi-center, phase III trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (AIPC)."...

2008-12-30 12:34:34

Researchers found a benign breast disease (BBD), known as atypical hyperplasia, can significantly increase a young woman's risk of developing breast cancer even if there is no breast cancer history in her family. Those diagnosed with atypical hyperplasia, a precancerous condition of the breast tissue, have a six-times greater risk of developing breast cancer than women without the disease. Researchers also examined the lifetime breast cancer risk of two other BBDs: non-proliferative BBD and...

2008-10-23 09:00:10

SEATTLE and GENEVA, Oct. 23 /PRNewswire-FirstCall/ -- Researchers from Dendreon Corporation today presented preclinical data on its lead small molecule candidate, D-3263, which targets Trp-p8 (a transmembrane cation channel protein also known as Trp-M8), supporting Trp-p8 as a therapeutic cancer target. The poster, titled, "Preclinical Validation of the TrpM8 Ion Channel as a Cancer/ Benign Prostate Hyperplasia Target," was presented at the European Organization for Research and Treatment...

2008-08-31 03:00:11

By Pereira-Fantini, Prue M Thomas, Sarah L; Taylor, Russell G; Nagy, Eva; Sourial, Magdy; Fuller, Peter J; Bines, Julie E Background: Colostrum protein concentrate (CPC) contains a high level of insulin-like growth factor-1 (IGF-1). IGF-1 and IGF binding protein (IGFBPs) may play an important role during the postresection adaptation response. As smooth muscle is an important site for IGF- 1 action in the intestine, this study aims to (1) investigate the effect of CPC supplementation on...

2006-04-04 14:10:00

WASHINGTON -- Women who took prescription pain relievers known as COX-2 inhibitors for at least two years were less likely to develop breast cancer than others who did not have a history of taking the drugs, a study released on Tuesday said. Researchers said they would not yet suggest use of COX-2 drugs for preventing breast cancer, in part because they have been linked to a higher risk of cardiovascular problems. The only COX-2 inhibitor now being sold in the United States is Pfizer Inc.'s...

2005-07-20 18:21:38

(Corrects to make clarification in first paragraph: "... the most common form of benign breast disease.") By Gene Emery BOSTON (Reuters) - Women diagnosed with the most common form of benign breast disease but who do not have a strong family history of breast cancer have no heightened risk of developing a tumor, according to a new study. "If women do not have a strong family history, the risk does not increase," said Lynn Hartmann, chief author of the report, which appears in Thursday's...

2005-07-20 16:45:11

By Gene Emery BOSTON (Reuters) - Women diagnosed with benign breast disease but who do not have a strong family history of breast cancer have no heightened risk of developing a tumor, according to a new study. "If women do not have a strong family history, the risk does not increase," said Lynn Hartmann, chief author of the report, which appears in Thursday's New England Journal of Medicine. "Most of what we're putting out there, I would put in the 'good news' category," Hartmann, an...